ロード中...
New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response
A recent decision by the Food and Drug Administration (FDA) to declare various brands of levothyroxine bioequivalent has provoked objections from several physicians' organizations. These organization assert that the method of testing bioequivalence is flawed, and that indiscriminate switching a...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2005
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2751497/ https://ncbi.nlm.nih.gov/pubmed/16146330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/aapsj070107 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|